The evidence that IL‐22 upregulates the expression of some of the membrane‐bound mucins in human epithelial cells suggests that treatment with IL‐22 may have a beneficial effect in conditions where patients are challenged with increased bacterial burden or a disrupted epithelial barrier, such as IBD or NEC. This evidence concerns the gene IL22 and inflammatory bowel disease.